NASDAQ:MACK Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free MACK Stock Alerts $14.75 +0.03 (+0.20%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$14.72▼$14.8050-Day Range$13.06▼$15.0052-Week Range$11.53▼$15.89Volume95,075 shsAverage Volume99,768 shsMarket Capitalization$214.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Merrimack Pharmaceuticals alerts: Email Address Merrimack Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy5.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 4 Articles This WeekInsider TradingAcquiring Shares$11,441 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 starsMedical Sector830th out of 939 stocksPharmaceutical Preparations Industry384th out of 435 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Merrimack Pharmaceuticals. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.02% of the outstanding shares of Merrimack Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverMerrimack Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Merrimack Pharmaceuticals has recently decreased by 5.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMerrimack Pharmaceuticals does not currently pay a dividend.Dividend GrowthMerrimack Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MACK. Previous Next 2.6 News and Social Media Coverage News SentimentMerrimack Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Merrimack Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for MACK on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merrimack Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,441.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.87% of the stock of Merrimack Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.97% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Merrimack Pharmaceuticals is -184.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Merrimack Pharmaceuticals is -184.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMerrimack Pharmaceuticals has a P/B Ratio of 11.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More MACK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MACK Stock News HeadlinesMarch 27, 2024 | businesswire.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 26, 2024 | americanbankingnews.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Crosses Above 200 Day Moving Average of $13.19March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 20, 2024 | americanbankingnews.comShort Interest in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Decreases By 5.9%March 8, 2024 | msn.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | investorplace.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 7, 2024 | businesswire.comMerrimack Reports Full Year 2023 Financial ResultsMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… February 22, 2024 | benzinga.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 15, 2024 | markets.businessinsider.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 14, 2024 | finance.yahoo.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 13, 2024 | msn.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | marketwatch.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)December 12, 2023 | msn.com$2M Bet On Ford? Check Out These 4 Stocks Insiders Are BuyingDecember 10, 2023 | finance.yahoo.comWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowNovember 10, 2023 | morningstar.comMerrimack Pharmaceuticals Inc MACKNovember 2, 2023 | finance.yahoo.comMerrimack Reports Third Quarter 2023 Financial ResultsOctober 24, 2023 | stockhouse.comOnconova Expands Leadership Team with Two Key AppointmentsOctober 20, 2023 | theglobeandmail.comThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC FirmAugust 15, 2023 | finance.yahoo.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 13, 2023 | insidermonkey.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptSee More Headlines Receive MACK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/27/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MACK CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-720-8606Fax617-491-1386Employees426Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-6.24% Return on Assets-6.09% Debt Debt-to-Equity RatioN/A Current Ratio43.50 Quick Ratio43.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book11.26Miscellaneous Outstanding Shares14,530,000Free Float10,337,000Market Cap$214.32 million OptionableOptionable Beta1.44 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Gary L. Crocker M.B.A. (Age 72)President, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman Comp: $76kDr. Ulrik B. Nielsen Ph.D. (Age 52)Co-Founder & Independent Director Comp: $72.5kDr. Anthony J. Sinskey Ph.D. (Age 84)Sc.D., Co-Founder and Scientific Advisor Comp: $4.25kGeoffrey Grande C.F.A.Senior Director of CommunicationsMs. Ellen K. Forest (Age 60)Head of Human Resources Dr. Daryl C. Drummond Ph.D. (Age 55)Head of Research Comp: $427.06kMr. Timothy R. Surgenor (Age 64)Secretary More ExecutivesKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLXOMANASDAQ:XOMAVerastemNASDAQ:VSTMEmergent BioSolutionsNYSE:EBSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 8,610 shares on 3/11/2024Ownership: 4.194%Vanguard Group Inc.Bought 8,610 shares on 2/15/2024Ownership: 4.252%Barclays PLCBought 12,535 shares on 2/15/2024Ownership: 0.100%Citadel Advisors LLCBought 1,600 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 549,418 shares on 2/14/2024Ownership: 3.837%View All Insider TransactionsView All Institutional Transactions MACK Stock Analysis - Frequently Asked Questions How have MACK shares performed in 2024? Merrimack Pharmaceuticals' stock was trading at $13.41 on January 1st, 2024. Since then, MACK shares have increased by 10.0% and is now trading at $14.75. View the best growth stocks for 2024 here. When is Merrimack Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our MACK earnings forecast. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) posted its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. When did Merrimack Pharmaceuticals' stock split? Merrimack Pharmaceuticals shares reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM). Who are Merrimack Pharmaceuticals' major shareholders? Merrimack Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.25%), Vanguard Group Inc. (4.19%), ADAR1 Capital Management LLC (3.84%), Dimensional Fund Advisors LP (3.04%), Northern Trust Corp (0.82%) and Barclays PLC (0.10%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen. View institutional ownership trends. How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MACK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.